Page 3 - ஒப்பந்த உற்பத்தி ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tetra Bio-Pharma wins a drug license to distribute REDUVO cannabinoid soft gel capsules in Canada The company said that the addressable market for the synthetic cannabinoid drug in Canada is pegged at around C$80 million by 2022 Armed with the drug license, Tetra said that it has now submitted a Cannabis Drug License application to Health Canada. Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, revealed that it has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO cannabinoid soft gel capsules in Canada. REDUVO is a synthetic THC-based soft gel capsule aimed as a therapy to combat severe nausea and vomiting associated with cancer chemotherapy. It is currently being assessed by Health Canada for the issuance of a Drug Identification Number (DIN). REDUVO, known as Marinol in the United States, has been approved as a regulated pharmaceutical drug by the US Food and Dr

United statesContract manufacturing organizationDrug administrationHealth canadaHealth canada drug establishment licenseHealth canada cannabis drug licenseDrug identification numberGuy chamberlandஒன்றுபட்டது மாநிலங்களில்ஒப்பந்த உற்பத்தி ஆர்கநைஸேஶந்ஆரோக்கியம் கனடாஆரோக்கியம் கனடா மருந்து ஸ்தாபனம் உரிமம்மருந்து அடையாளம் எண்பையன் சேம்பர்லேண்ட்